Table 3.
Randomized clinical trials of hypofractionated whole breast/chest wall radiotherapy
| Trial | Period | n | Hypofraction schedule | SIB | Mastectomy | Regional nodes | IMRT/ IGRT | Chemo-therapy | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Hôpital Necker (*) [32] |
1982- |
230 |
5.75 Gy x 4 F/ 17 |
No |
Yes |
? |
NS |
Yes |
= |
| 1984 |
days |
||||||||
| Royal Marsden Hospital [33] |
1986- |
1410 |
3 Gy x 13 F/ 5 |
No |
No |
Yes |
NS |
No |
More local relapses |
| 1998 |
weeks |
||||||||
| Royal Marsden Hospital |
|
|
3.3 Gy x 13 F/ 5 |
No |
No |
Yes |
NS |
No |
= |
| weeks | |||||||||
| Ontario [18] |
1993- |
1234 |
2.66 Gy x 16 F/ 3 |
No |
No |
No |
NS |
Yes |
= |
| 1996 |
weeks |
||||||||
| UK Start A [19] |
1998- |
2236 |
3 Gy x 13 F/ 5 |
No |
Yes |
Yes |
NS |
Yes |
More local relapses |
| 2002 |
weeks |
||||||||
| UK Start A |
|
|
3.2 Gy x 13 F/ 5 |
No |
Yes |
Yes |
NS |
Yes |
= |
| weeks | |||||||||
| Lahore [34] |
1998- |
300 |
5.4 Gy x 5 F/ 1 |
No |
Yes |
Yes |
NS |
Yes |
= |
| 2004 |
week |
||||||||
| Lahore |
|
|
3.5 Gy x 10 F/ 2 |
No |
Yes |
Yes |
NS |
Yes |
= |
| weeks | |||||||||
| Lahore |
|
|
2.66 Gy x 15 F/ 3 |
No |
Yes |
Yes |
NS |
Yes |
Control arm |
| weeks | |||||||||
| UK Start B [20] |
1999- |
2215 |
2.67 Gy x 15 F/ 3 |
No |
Yes |
Yes |
NS |
Yes |
= |
| 2001 |
weeks |
||||||||
| Egypt NCI [35] |
2002- |
30 |
2.66 Gy x 16 F/ 3 |
No |
No |
No |
NS |
No |
Boost in conventional arm |
| 2003 |
weeks |
||||||||
| UK FAST [36] |
2004- |
915 |
5.7 Gy x 5 F/ 5 |
? |
No |
No |
Yes |
No |
= |
| 2007 |
weeks |
||||||||
| UK FAST |
|
|
6 Gy x 5 F/ 5 |
? |
No |
No |
Yes |
No |
More breast toxicity |
| weeks | |||||||||
| DBCG 2009 RT Hypo [37] |
2009- |
1500** |
2.67 Gy x 15 F/ 3 |
No |
No |
No |
Yes |
Yes |
On-going |
| weeks | |||||||||
| UK IMPORT HIGH |
2009- |
840** |
2.4 Gy [SIB 3.2 Gy] |
Yes |
No |
? |
Yes |
? |
On-going |
| x 15 F/ | |||||||||
| UK IMPORT HIGH |
|
|
2.4 Gy [SIB 3.53 Gy] |
Yes |
No |
? |
Yes |
? |
|
| x 15 F/ | |||||||||
| UZ Brussel |
2007- |
122 |
2.8 Gy [SIB 3.4 Gy] |
Yes |
Yes |
Yes |
Yes |
Yes |
Closed for inclusion; FU on-going |
| [this study] | x 15 F/ 3 weeks | ||||||||
(*) Partial report; full study 1982–1989, n = 525 patients. (**) Planned accrual.
NS: not stated. =: outcome comparable with control arm. SIB: simultaneous integrated boost. FU: follow-up.